Nifty Healthcare Index News and Updates

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1174.80

-2.14%

US tariffs on Pharma: Dr Reddy's to Sun Pharmacan Indian drugmakers escape Trump's tariff tantrums?

livemint

US tariffs on Pharma: India currently levies up to 10% import duties on drugs imported from the US with several drugs having lower duty of 5% while around 150 drugs are exempted from duties.

Dr. Reddy's Laborato.. has an average target of 1347.12 from 10 brokers.

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1174.80

-2.14%

Kyndryl partners with Dr Reddy's to automate IT ops with AI-powered platform

Business Line

The initiative will implement a Zero Touch IT Operations model using Kyndryl's Dual Model IT Ops framework, targeting a 60% reduction in manual interventions

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Apollo Hospitals Enterprise Ltd.

07 Apr 2025

6953.00

-2.88%

Chronic illnesses rising without symptoms: Apollo Hospitals study

Business Line

The Health of the Nation 2025 report by Apollo Hospitals reveals that millions of Indians are living with undiagnosed chronic conditions like hypertension and diabetes.

Apollo Hospitals Ent.. has an average target of 7471.80 from 5 brokers.

Sun Pharmaceutical Industries Ltd.

07 Apr 2025

1787.40

-0.91%

Sun Pharma launches Fexuprazan tablets for Erosive Esophagitis treatment

Business Standard

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product is approved as a new treatment for adults with Erosive Esophagitis of all grades, it added. Sun Pharma has obtained rights from South Korea-based Daewoong Pharmaceutical to manufacture and commercialise the medication in India. As per the agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties, it said. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. Fexuclue is a best-in-class treatment option with the potential to bridge this gap," Sun Pharma CEO India Business Kirti Ganorkar...

Emkay released a Buy report for Sun Pharmaceutical Industries Ltd. with a price target of 2400.0 on 10 Apr, 2025.

Dr. Reddy's Laboratories Ltd.

07 Apr 2025

1174.80

-2.14%

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

Business Standard

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr. Reddy's Laboratories Ltd. is trading below its 100 day SMA of 1221.3

Dr. Reddy's Laboratories Ltd.

05 Apr 2025

1174.80

-2.14%

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Business Standard

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's faces 2,395 crore tax reassessment notice

Business Line | 05 Apr 2025

Biocon Ltd.

04 Apr 2025

311.85

-4.56%

Biocon Board Approves Rs 600 Crore Fundraising Through Private Placement of Commercial Papers

NDTV Profit

It, however, did not disclose reasons for raising the capital.

Biocon Ltd. has an average target of 402.75 from 4 brokers.

Sun Pharmaceutical Industries Ltd.

04 Apr 2025

1787.40

-0.91%

Higher tariffs may significantly dent profits of pharma companies

Business Standard

Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Laurus Labs Ltd.

04 Apr 2025

625.65

-3.08%

Laurus Labs to invest 5,000 crore in new manufacturing plant in Andhra Pradesh

Business Line

The State government will allot land for the proposed plant in Rambilli village, Anakapalli district

Laurus Labs Ltd. has an average target of 621.00 from 4 brokers.

Torrent Pharmaceuticals Ltd.

03 Apr 2025

3238.90

-2.59%

Pharma stocks that you can keep in your portfolio despite US tariff woes

Business Standard

Tausif Shaikh, India analyst for pharma and healthcare, BNP Paribas India, prefers domestic-focused companies like Torrent Pharmaceuticals, and JB Chemicals and Pharmaceuticals in the sector

Torrent Pharmaceutic.. has an average target of 3522.40 from 6 brokers.

Nifty Healthcare Index PB	5.9
Nifty Healthcare Index PE	38.0
Nifty Healthcare Index DIV	0.5
Nifty Healthcare Index EPS	363.6

Nifty Healthcare Index PB

Nifty Healthcare Index PE

Nifty Healthcare Index DIV

Nifty Healthcare Index EPS

Nifty Healthcare Index News and Updates

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.